Sirak Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 15-12-2024
- Paid Up Capital ₹ 1.34 Cr
as on 15-12-2024
- Company Age 17 Year, 8 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 11.48 Cr
as on 15-12-2024
- Satisfied Charges ₹ 4.95 Cr
as on 15-12-2024
- Revenue 80.33%
(FY 2022)
- Profit 189.85%
(FY 2022)
- Ebitda 201.04%
(FY 2022)
- Net Worth 99.67%
(FY 2022)
- Total Assets 28.85%
(FY 2022)
About Sirak Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.34 Cr.
The company currently has active open charges totaling ₹11.48 Cr. The company has closed loans amounting to ₹4.95 Cr, as per Ministry of Corporate Affairs (MCA) records.
Satya Vakkalanka, Swaroopkumar Vakkalanka, and Thappali Manikandan serve as directors at the Company.
- CIN/LLPIN
U24232TG2008PTC057045
- Company No.
057045
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jan 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Sirak Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Swaroopkumar Vakkalanka  | Director | 08-Jan-2008 | Current |
| Satya Vakkalanka | Director | 08-Jan-2008 | Current |
| Thappali Manikandan | Director | 31-Mar-2022 | Current |
Financial Performance of Sirak Pharmaceuticals.
Sirak Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 80.33% increase. The company also saw a substantial improvement in profitability, with a 189.85% increase in profit. The company's net worth Soared by an impressive increase of 99.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sirak Pharmaceuticals?
Unlock access to Sirak Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Incozen Therapeutics Private LimitedActive 16 years 6 monthsSatya Vakkalanka and Thappali Manikandan are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 06 Feb 2024 | ₹4.03 Cr | Open |
Yes Bank Limited Creation Date: 29 Oct 2022 | ₹7.45 Cr | Open |
Yes Bank Limited Creation Date: 29 Feb 2020 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Sirak Pharmaceuticals?
Unlock and access historical data on people associated with Sirak Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sirak Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sirak Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
